Skip to content Skip to footer
Subscribe Now
VIEWPOINTS

Evorpacept’s Momentum in HER2+ Gastric Cancer: A Conversation with Jason Lettmann from ALX Oncology 

Shots:  Evorpacept emerges as the only CD47-blocking therapy with strong clinical activity and a highly manageable safety profile, thanks to its unique inactive Fc design that enables targeted tumor destruction while sparing healthy cells  Updated ASPEN-06 data highlights CD47 overexpression as a powerful predictive biomarker, showing dramatic improvements in ORR, DOR, PFS, and OS for patients with…
December 3, 2025

Read more

VIEWPOINTS

Inside Sapient’s Multi-Omics Revolution: A Deep Dive with Founder Mo Jain 

Shots:    Sapient’s new partnership with Alamar Biosciences supercharges its multi-omics engine, bringing the ultra-sensitive NULISA™ platform in-house to capture hard-to-measure cytokines and chemokines, unlocking deeper biological insights beyond the reach of mass spectrometry alone  The collaboration with Rancho Biosciences is redefining large-scale data intelligence, enabling Sapient’s DynamiQ™ platform to seamlessly integrate, structure, and analyze massive multi-omics and real-world…
December 1, 2025

Read more

VIEWPOINTS

Tariffs, Compliance, and the Future of Drug Pricing: A Conversation with Jesse Mendelsohn from Model N 

Shots:    U.S. tariff shifts are forcing pharma manufacturers to accelerate reshoring, reduce duty exposure, and stabilize pricing, fueling renewed investment in onshore final manufacturing, Most Favored Nation pricing strategies, and selective direct-to-consumer pilots to secure tariff relief amid policy volatility  As pricing, reimbursement, market access, and trade regulations evolve, companies are prioritizing late-stage, lower-risk…
November 24, 2025

Read more

VIEWPOINTS

Inside neffy’s Launch Strategy: A Stimulating Conversation with Richard Lowenthal, CEO & Co-Founder of ARS Pharmaceuticals 

Shots:  Inconsistent access to epinephrine auto-injectors continues to be a major unmet need in the management of anaphylaxis  neffy, an innovative intranasal epinephrine spray, provides a needle-free alternative for the emergency treatment of severe allergic reactions, including anaphylaxis, in adults and children aged four years and older who weigh at least 33 lbs  Richard Lowenthal,…
November 3, 2025

Read more

VIEWPOINTS

Optimizing Life Sciences CRM: A Candid Conversation with Akshay Kapadia from Conexus Solutions 

Shots:  As life sciences organizations increasingly adopt integrated data, AI, and advanced analytics, CRM platforms are becoming powerful tools to anticipate customer needs, personalize engagements, and measure impact in real-time across multiple channels    In the coming years, CRM will transform into a strategic intelligence hub, empowering teams to make data-driven decisions and helping companies…
October 27, 2025

Read more

Announcements

PharmaShots Ranked Among the Top 10 in Feedspot’s “45 Best Indian Pharma Blogs & Websites 2025” 

PharmaShots is proud to announce that we have been ranked 6th among the “45 Best Indian Pharma Blogs and Websites in 2025” by Feedspot, a leading platform that curates the best online content across industries.  This recognition underscores our commitment to delivering concise, credible, and high-impact biopharma and healthcare insights to our global audience. Being featured alongside some of…
October 18, 2025

Read more

EXCLUSIVE

Exclusive: A Stimulating Dialogue with Edmund Ben Ami, Co-Founder & CEO of NeuraLight 

Shots:  Given the high variability and subjectivity of traditional clinical scales, there is an urgent need for objective biomarkers to assess CNS disease progression more reliably    NeuraLight is at the forefront of precision neurology, developing objective and sensitive biomarkers that bring greater accuracy and consistency to CNS research    In this exclusive conversation, Edmund…
October 14, 2025

Read more

Load more